Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder

Journal of the American Veterinary Medical Association

Volumn 239, Issue 8, 2011, Pages 1084-1089

  McMillan, Sarah K ^a   Boria, Pedro ^b   Moore, George E ^a   Widmer, William R ^a   Bonney, Patty L ^a   Knapp, Deborah W ^a  

^a PURDUE UNIVERSITY   (United States)

^b Vet Specialists Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DERACOXIB; SULFONAMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; MALE; TOXIC HEPATITIS; TRANSITIONAL CELL CARCINOMA; UREMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOTEMIA; CARCINOMA, TRANSITIONAL CELL; DOG DISEASES; DOGS; DRUG-INDUCED LIVER INJURY; FEMALE; MALE; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

CANIS FAMILIARIS;

EID: 80054049161     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.239.8.1084     Document Type: Article

References (27)

1. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144.
2. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
3. Withrow SJ, Gillette EL, Hoopes PJ, et al. Intraoperative irradiation of 16 spontaneously occurring canine neoplasms. Vet Surg 1989;18:7-11.
4. Poirier VJ, Forrest LJ, Adams WM, et al. Piroxicam, mitoxantrone, and course fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. J Am Anim Hosp Assoc 2004;40:131-136.
5. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
6. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
7. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
8. Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc 1994;30:270-275.
9. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
10. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
11. Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Small animal clinical oncology. 4th ed. Philadelphia: Saunders, 2007;649-658.
12. Curry SL, Cogar SM, Cook JL. Nonsteroidal anti-inflammatory drugs: a review. J Am Vet Anim Hosp 2005;41:298-309.
13. Khan KN, Knapp DW, Denicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
14. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-5650.
15. Margulis V, Shariat SF, Ashfaq R, et al. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 2007;177:1163-1168.
16. Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:812-817.
17. Deramaxx (deracoxib) [package insert]. Greensboro, NC: Novartis Animal Health, 2002.
18. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-353.
19. Owens L. TNM classification of tumors in domestic animals. Geneva: World Health Organization, 1980;34.
20. Group VCO. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
21. Dhawan D, Jeffreys AB, Zheng R, et al. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008;7:897-904.
22. Hampshire VA, Doddy FM, Post LO, et al. Adverse drug event reports at the United States Food and Drug Administration Center for Veterinary Medicine. J Am Vet Med Assoc 2004;225:533-536.
23. MacPhail CM, Lappin MR, Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998;212:1895-1901.
24. Roberts ES, Van Lare KA, Marable BR, et al. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J Vet Pharmacol Ther 2009;32:329-337.
25. Sennello KA, Leib MS. Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. J Vet Intern Med 2006;20:1291-1296.
26. Sellers RS, Senese PB, Khan KN. Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug Chem Toxicol 2004;27:111-122.
27. Silverman LR, Khan KN. "Have you seen this?" Nonsteroidal anti-inflammatory drug-induced renal papillary necrosis in a dog. Toxicol Pathol 1999;27:244-245.